Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03229200
Recruitment Status : Enrolling by invitation
First Posted : July 25, 2017
Last Update Posted : January 29, 2020
Sponsor:
Information provided by (Responsible Party):
Pharmacyclics Switzerland GmbH

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Enrolling by invitation
Estimated Primary Completion Date : July 2, 2027
Estimated Study Completion Date : July 2, 2027